2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.
Oncologists are now used to doing echocardiograms, which do not require any isotopes and yield rich results, or multigated acquisition (MUGA) scans, which yield results as one simple number.
Muss hypothesizes that in 5-10 years, the best way to monitor cardiac toxicity may be with an MRI of the heart and that those who are researching heart MRI are seeing incredible results.
Related Content: